Objective:Long-acting darbepoetin-α (DA)
has recently been used to treat renal anemia in patients with chronic renal
failure. It is considered clinically useful because its duration of action is
longer than that of conventional epoetin-α.
In this study, we investigated changes in the levels of the oxidative stress
marker malondialdehyde-modified low density lipoprotein (MDA-LDL), renal
anemia, and renal function when patients were treated for chronic renal failure switched from epoetin-α to DA.Materials and Methods:The subjects included
nine patients with chronic renal failure and renal anemia who were treated withepoetin-α on anoutpatient basis at our department. Blood was sampled prior to the
switch and at 3, 6, and 12 months after the switch. We then investigated
changes in MDA-LDL, hemoglobin (Hb), and creatinine (Cr) levels.
References
[1]
Kuriyama, S., Tomonari, H., Yoshida, H., Hashimoto, T., Kawaguchi, Y. and Sakai, O. (1997) Reversal of Anemia by Erythropoietin Therapy Retards the Progression of Chronic Renal Failure, Especially in Nondiabetic Patients. Nephron, 77, 176-185. http://dx.doi.org/10.1159/000190270
[2]
Hayashi, T., Suzuki, A., Shoji, T., Togawa, M., Okada, N., Tsubakihara, Y., Imai, E. and Hori, M. (2000) Cardiovascular Effect of Normalizing the Hematocrit Level during Erythropoietin Therapy in Predialysis Patients with Chronic Renal Failure. American Journal of Kidney Diseases, 35, 250-256. http://dx.doi.org/10.1016/S0272-6386(00)70334-9
[3]
Kiss, Z., Elliott, S., Jedynasty, K., Tesar, V. and Szegedi, J. (2010) Discovery and Basic Pharmacology of Erythropoiesis-Stimulating Agents (ESAs), Including the Hyperglycosylated ESA, Darbepoetin Alfa: An Update of the Rationale and Clinical Impact. European Journal of Clinical Pharmacology, 66, 331-340. http://dx.doi.org/10.1007/s00228-009-0780-y
[4]
Libetta, C., Sepe, V., Esposito, P., Galli, F. and Al Canton, D.A. (2011) Oxidative Stress and Inflammation: Implications in Uremia and Hemodialysis. Clinical Biochemistry, 44, 1189-1198.
[5]
Sung, C.C., Hsu, Y.C., Chen, C.C., Lin, Y.F. and Wu, C.C. (2013) Oxidative Stress and Nucleic Acid Oxidation in Patients with Chronic Kidney Disease. Oxidative Medicine and Cellular Longevity, 2013, Article ID: 301982.
[6]
Parissis, J.T., Kourea, K., Andreadou, I., Ikonomidis, I., Markantonis, S., Ioannidis, K., Paraskevaidis, I., Iliodromitis, E., Filippatos, G. and Kremastinos, D.T. (2009) Effects of darbepoetin alfa on Plasma Mediators of Oxidative and Nitrosative Stress in Anemic Patients with Chronic Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 103, 1134-1138. http://dx.doi.org/10.1016/j.amjcard.2008.12.041
[7]
Malgorzewics, S., Lichodziejewska-Niemierko, M., Lizakowski, S., Liberek, T., Lysiak-Szydiowska, W. and Rutkowski, B. (2010) Oxidative Stress, Inflammation and Nutritional Status during Darbepoetin α-Treatment in Peritoneal Dialysis Patients. Clinical Nephrology, 73, 210-215.
[8]
Lopes-Virella, W.F., Hunt, K.J., Baker, N.L., Virella, G., Moritz, T. and VADT Investigators (2012) The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis, 224, 526-531. http://dx.doi.org/10.1016/j.atherosclerosis.2012.08.006
[9]
Yang, W.S., Chang, J.W., Han, N.J. and Park, S.-K. (2011) Darbepoetinalfa Suppresses Tumor Necrosis Factor—An Induced Endothelin-1 Production through Antioxidant Action in Human Aortic Endothelial Cells: Role of Sialic Acid Residues. Free Radical Biology & Medicine, 50, 1242-1251. http://dx.doi.org/10.1016/j.freeradbiomed.2011.02.005
